Technology
Health
Biotechnology

Syros

1,906

$4.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-2.11%) Today
$0.00 (0.00%) As of 4:44 PM EST after-hours

Why Robinhood?

You can buy or sell Syros and other stocks, options, ETFs, and crypto commission-free!

About SYRS

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Read More The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

CEO
Nancy A. Simonian
Employees
76
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
202.87M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
201.09K
High Today
$4.80
Low Today
$4.62
Open Price
$4.72
Volume
105.65K
52 Week High
$11.93
52 Week Low
$4.53

Collections

Technology
Health
Biotechnology
Cancer Prevention
2016 IPO
US
North America
Female CEOs

SYRS News

BenzingaDec 2

Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award reco
63

SYRS Earnings

-$0.57
-$0.51
-$0.45
-$0.39
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Mar 5, Pre-Market

You May Also Like

ROSEU
DRIO
PUYI
DCI
HDGE
BSMX
MYOS
GPAQW
TRU
DLNG
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy SYRS

Market Price$4.64
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell Syros stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up